82 related articles for article (PubMed ID: 26084515)
1. Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans.
Pleguezuelos O; Robinson S; Fernandez A; Stoloff GA; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Aug; 22(8):949-56. PubMed ID: 26084515
[TBL] [Abstract][Full Text] [Related]
2. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
[TBL] [Abstract][Full Text] [Related]
3. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
5. Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Trujillo A; Barnes J; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2015 Jun; 15(6):654-62. PubMed ID: 25788164
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
Watson JM; Francis JN; Mesens S; Faiman GA; Makin J; Patriarca P; Treanor JJ; Georges B; Bunce CJ
Virol J; 2015 Feb; 12():13. PubMed ID: 25645025
[TBL] [Abstract][Full Text] [Related]
7. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
[TBL] [Abstract][Full Text] [Related]
10. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
[TBL] [Abstract][Full Text] [Related]
11. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.
Ambrose CS; Wu X; Jones T; Mallory RM
Vaccine; 2012 Nov; 30(48):6794-801. PubMed ID: 23000125
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
13. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
14. Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model.
Han A; Poon JL; Powers JH; Leidy NK; Yu R; Memoli MJ
BMC Infect Dis; 2018 Jul; 18(1):353. PubMed ID: 30055573
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
[TBL] [Abstract][Full Text] [Related]
16. Specific formulation of Camellia sinensis prevents cold and flu symptoms and enhances gamma,delta T cell function: a randomized, double-blind, placebo-controlled study.
Rowe CA; Nantz MP; Bukowski JF; Percival SS
J Am Coll Nutr; 2007 Oct; 26(5):445-52. PubMed ID: 17914132
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral intake of plasmacytoid dendritic cells-stimulative lactic acid bacterial strain on pathogenesis of influenza-like illness and immunological response to influenza virus.
Sugimura T; Takahashi H; Jounai K; Ohshio K; Kanayama M; Tazumi K; Tanihata Y; Miura Y; Fujiwara D; Yamamoto N
Br J Nutr; 2015 Sep; 114(5):727-33. PubMed ID: 26234407
[TBL] [Abstract][Full Text] [Related]
18. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues.
Nguyen HH; Moldoveanu Z; Novak MJ; van Ginkel FW; Ban E; Kiyono H; McGhee JR; Mestecky J
Virology; 1999 Feb; 254(1):50-60. PubMed ID: 9927573
[TBL] [Abstract][Full Text] [Related]
19. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study.
Memoli MJ; Czajkowski L; Reed S; Athota R; Bristol T; Proudfoot K; Fargis S; Stein M; Dunfee RL; Shaw PA; Davey RT; Taubenberger JK
Clin Infect Dis; 2015 Mar; 60(5):693-702. PubMed ID: 25416753
[TBL] [Abstract][Full Text] [Related]
20. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
